West Pharmaceutical Services Reports Strong Q3 2026 Results and Raises Full-Year Guidance

West Pharmaceutical Services, Inc. (NYSE: WST) Q3 2026 Earnings Report Summary

Overview

On October 29, 2026, West Pharmaceutical Services, Inc. filed a Current Report on Form 8-K under Items 2.02 and 7.01 to disclose its third-quarter 2026 financial results and updated full-year 2026 guidance.

Q3 2026 Financial Highlights

• Net Sales: $874.5 million, up 8.7% compared to Q3 2025 ($804.6 million); organic growth was 11.9%.
• Diluted EPS: $3.02, up 57.3% from the prior-year period.
• Adjusted-Diluted EPS: $2.66, an increase of 35.7% YoY.
• Operating Profit: $267.4 million (31% of sales), compared to $167.6 million (21% of sales) in Q3 2025.
• Gross Profit: $347.4 million (40% margin) vs. $294.3 million (37% margin) in Q3 2025.

Segment Performance

• Proprietary Products Segment: Net sales reached $728.8 million, up 12.6% (16.6% organic).
  • High-Value Product (HVP) Components: $466.7 million (+19.7% reported, +20.3% organic), representing 53% of total net sales.
  • HVP Delivery Devices: $99.1 million (flat reported, +26.4% organic excluding FX and SmartDose® 3.5mL divestiture).
  • Standard Products: $163.0 million (+2.9% reported, +3.1% organic).
• West Vantage Segment: Net sales of $145.7 million declined 7.3% (-6.6% organic), representing 17% of total sales.

Capital Allocation & Cash Flow

• Share Repurchases: $231 million during Q3 2026, bringing year-to-date repurchases to $685 million.
• Dividends: Declared Q4 dividend of $0.26 per share (+18% increase from $0.22 in Q3).
• Cash Flow & Capex: YTD operating cash flow totaled $403 million; capital expenditures were $125 million.

Upwardly Revised Full-Year 2026 Guidance

• Net Sales: Raised to $3.410 billion – $3.420 billion (prior: $3.345 billion – $3.380 billion).
• Organic Net Sales Growth: Increased to 11.3% – 11.6% (prior: 10% – 11%).
• Adjusted-Diluted EPS: Raised to $9.38 – $9.48 (prior: $8.85 – $9.05).
• Capital Spending: Lowered to $215 million – $220 million (prior: $250 million – $275 million).